Jesse Mondry
by

psilocybin therapy

Earlier this year we wrote about the movement to decriminalize psilocybin – noting its success in Denver, Oakland, and Santa Cruz – and that nearly 100 other cities are looking at decriminalizing psychedelics. (The Psilocybin Movement is Like the Cannabis Movement (Except When It’s Not)). That article posited that psilocybin would move along two tracks similar to cannabis (medical and pharmaceutical) before approaching the “retail model” initiatives that became standard with adult use cannabis.

We also have been tracking the use of ketamine to treat depression and litigation related thereto:

In the first article, we noted the proliferation of ketamine clinics and the larger trend of the health care provider community in exploring alternative therapies and emerging medicine, including the use of psilocybin.

A paper recently published by the National Academy of Scientists may prove groundbreaking in helping us understand why psilocybin is “showing considerable promise as a therapeutic intervention for neuropsychiatric disorders including depression, anxiety, and addiction,” according to its authors. I’ll be the first to confess that the science described in the paper is beyond me, but this article by Georgia Perry does a good job. Ms. Perry writes that “an international team of scientists created a biophysically realistic whole-brain model . . . [which] enabled them to observe how psilocybin impacts the activity of neurons and neurotransmitters.”  The researchers found that psilocybin disrupted neural networks and neurotransmitters formed new pathways.

Although ketamine clinics may provide a roadmap for psilocybin clinics, a key difference is that psilocybin remains a Schedule I drug under the Controlled Substances Act. This means psilocybin is defined as having a high potential for abuse and no recognized medical uses. (Marijuana is defined the same way and this did not stop legalization efforts.) Ketamine is a defined as Schedule III drug. So in the near term, the differing treatment between ketamine and psilocybin likely will prevent an explosion of clinics offering treatment.

That said, let’s hope scientific research into psilocybin as a treatment for depression continues and that research results are taken seriously by legislators and others who have the ability to change our laws and policies.

For more reading on psilocybin, check out the following:

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

 
 

About this Blog

The Canna Law Blog™ is a forum for discussion about the practical aspects of cannabis law and how it impacts those involved in this growing industry. We will provide insight into how canna businesspeople can use the law to their advantage…

Read More

 
 

Stay Connected

   

 

SUBSCRIBE BY EMAIL

 
 

Topics

Archives

 
 
 
 

Disclaimer

Please be mindful that possessing, using, distributing and selling marijuana are all federal crimes and that this blog is not intended to give you any legal advice, much less lead you to believe that marijuana is legal under federal law.

 
 

COVID-19 Update: Since March 5, all of our attorneys and staff have been working remotely to ensure social distancing.
We are continuing to work on our clients’ matters and we are still accepting new clients. We are here for you.

 

You can reach us by phone at (206) 224-5657 or by email at firm@harrisbricken.com.

 

Stay healthy and stay safe!

Learn More
X